59 North Communications
  • 59 North Communications
  • Quotes
  • Share:
  • Subscribe:
  • news.cision.com/
  • 59 North Communications/
  • Atrogi receives regulatory approval from German health authority BfArM to initiate phase 1 study of ATR-258 in type 2 diabetes/
  • Atrogi Alexandra Ekman Ryding

Atrogi Alexandra Ekman Ryding

Tue, Mar 22, 2022 08:00 CET

Low resolution

Medium resolution

Original resolution

Subscribe

Related Releases

Atrogi announces first patient treated with its ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes Wed, Jan 25, 2023 08:30 CET
©Cision
Privacy statement | Cookies | About | Content Policy | Contact    Cision
©Cision Privacy statement Cookies About Content Policy Contact

   Cision